Switch to:
Also traded in: Austria, Brazil, Chile, Germany, Italy, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.04
GILD's Cash-to-Debt is ranked lower than
82% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. GILD: 1.04 )
Ranked among companies with meaningful Cash-to-Debt only.
GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.45 Max: 4122.75
Current: 1.04
0.15
4122.75
Equity-to-Asset 0.36
GILD's Equity-to-Asset is ranked lower than
82% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GILD: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 0.98
Current: 0.36
0.21
0.98
Debt-to-Equity 1.20
GILD's Debt-to-Equity is ranked lower than
88% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. GILD: 1.20 )
Ranked among companies with meaningful Debt-to-Equity only.
GILD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.39 Max: 2.96
Current: 1.2
0
2.96
Debt-to-EBITDA 2.38
GILD's Debt-to-EBITDA is ranked lower than
57% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. GILD: 2.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GILD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.33  Med: 1.16 Max: 2.11
Current: 2.38
0.33
2.11
Interest Coverage 8.37
GILD's Interest Coverage is ranked lower than
85% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 8.37 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 25.36 Max: 50.66
Current: 8.37
11.11
50.66
Piotroski F-Score: 5
Altman Z-Score: 3.09
Beneish M-Score: -3.22
WACC vs ROIC
9.00%
6.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 41.95
GILD's Operating Margin % is ranked higher than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. GILD: 41.95 )
Ranked among companies with meaningful Operating Margin % only.
GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.37 Max: 68
Current: 41.95
40.39
68
Net Margin % 7.12
GILD's Net Margin % is ranked higher than
82% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. GILD: 7.12 )
Ranked among companies with meaningful Net Margin % only.
GILD' s Net Margin % Range Over the Past 10 Years
Min: 17.73  Med: 36.8 Max: 55.48
Current: 7.12
17.73
55.48
ROE % 7.19
GILD's ROE % is ranked higher than
87% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. GILD: 7.19 )
Ranked among companies with meaningful ROE % only.
GILD' s ROE % Range Over the Past 10 Years
Min: 23.53  Med: 48.5 Max: 106.64
Current: 7.19
23.53
106.64
ROA % 2.40
GILD's ROA % is ranked higher than
83% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. GILD: 2.40 )
Ranked among companies with meaningful ROA % only.
GILD' s ROA % Range Over the Past 10 Years
Min: 7.27  Med: 26.05 Max: 42.28
Current: 2.4
7.27
42.28
ROC (Joel Greenblatt) % 290.44
GILD's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. GILD: 290.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 161.64  Med: 191.37 Max: 595.52
Current: 290.44
161.64
595.52
3-Year Revenue Growth Rate 9.40
GILD's 3-Year Revenue Growth Rate is ranked higher than
63% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GILD: 9.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 39.6 Max: 162.8
Current: 9.4
0
162.8
3-Year EBITDA Growth Rate 6.80
GILD's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GILD: 6.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.4 Max: 118.3
Current: 6.8
0
118.3
3-Year EPS without NRI Growth Rate -21.80
GILD's 3-Year EPS without NRI Growth Rate is ranked lower than
77% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. GILD: -21.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.1 Max: 113.8
Current: -21.8
0
113.8
GuruFocus has detected 2 Warning Signs with Gilead Sciences Inc GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GILD's 30-Y Financials

Financials (Next Earnings Date: 2019-02-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

GILD Guru Trades in Q4 2017

Jeremy Grantham 9,300 sh (New)
Steven Cohen 241,904 sh (New)
Paul Tudor Jones 3,947 sh (New)
Diamond Hill Capital 50,942 sh (New)
David Dreman 14,827 sh (+35.63%)
T Rowe Price Equity Income Fund 3,360,000 sh (+9.45%)
Dodge & Cox 15,416,361 sh (+55.57%)
John Rogers 2,236,337 sh (+3.08%)
NWQ Managers 484,957 sh (+5.58%)
Jeff Auxier 8,280 sh (+1.85%)
Pioneer Investments 9,054,685 sh (+53.30%)
Eaton Vance Worldwide Health Sciences Fund 505,918 sh (+8.85%)
Ronald Muhlenkamp 24,700 sh (unchged)
First Eagle Investment 59,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Murray Stahl 9,400 sh (unchged)
Tom Gayner 33,000 sh (unchged)
David Carlson 370,000 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Mario Gabelli 13,580 sh (unchged)
Jerome Dodson 646,000 sh (unchged)
Richard Pzena Sold Out
Ken Fisher 442,774 sh (-5.67%)
Ronald Muhlenkamp 220,613 sh (-1.58%)
Joel Greenblatt 664,792 sh (-4.57%)
Charles Brandes 65,796 sh (-6.36%)
John Buckingham 67,909 sh (-1.22%)
Jim Simons 7,564,948 sh (-26.06%)
» More
Q1 2018

GILD Guru Trades in Q1 2018

John Hussman 50,800 sh (New)
Caxton Associates 13,202 sh (New)
Ken Fisher 528,459 sh (+19.35%)
Ronald Muhlenkamp 222,377 sh (+0.80%)
Dodge & Cox 15,445,461 sh (+0.19%)
NWQ Managers 598,221 sh (+23.36%)
John Buckingham 69,480 sh (+2.31%)
Jeff Auxier 8,375 sh (+1.15%)
Steven Cohen 3,078,566 sh (+1172.64%)
Paul Tudor Jones 24,091 sh (+510.36%)
Diamond Hill Capital 1,054,552 sh (+1970.10%)
Ronald Muhlenkamp 2,200 sh (unchged)
Tom Gayner 33,000 sh (unchged)
Jeremy Grantham 9,300 sh (unchged)
David Carlson 370,000 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 505,918 sh (unchged)
Jerome Dodson 646,000 sh (unchged)
First Eagle Investment Sold Out
David Dreman 13,871 sh (-6.45%)
T Rowe Price Equity Income Fund 3,340,000 sh (-0.60%)
Joel Greenblatt 537,302 sh (-19.18%)
Charles Brandes 61,073 sh (-7.18%)
John Rogers 2,169,319 sh (-3.00%)
Murray Stahl 9,000 sh (-4.26%)
Jim Simons 5,032,800 sh (-33.47%)
Pioneer Investments 8,492,823 sh (-6.21%)
Mario Gabelli 12,980 sh (-4.42%)
» More
Q2 2018

GILD Guru Trades in Q2 2018

Stanley Druckenmiller 1,205,300 sh (New)
Ray Dalio 52,316 sh (New)
Ken Fisher 559,568 sh (+5.89%)
T Rowe Price Equity Income Fund 3,530,000 sh (+5.69%)
Dodge & Cox 16,259,811 sh (+5.27%)
Charles Brandes 61,897 sh (+1.35%)
John Rogers 2,329,260 sh (+7.37%)
NWQ Managers 721,158 sh (+20.55%)
Jeremy Grantham 9,600 sh (+3.23%)
David Carlson 450,000 sh (+21.62%)
Jeff Auxier 8,475 sh (+1.19%)
Steven Cohen 3,170,731 sh (+2.99%)
Paul Tudor Jones 27,855 sh (+15.62%)
Diamond Hill Capital 1,632,142 sh (+54.77%)
Mario Gabelli 14,980 sh (+15.41%)
Ronald Muhlenkamp 2,200 sh (unchged)
Murray Stahl 9,000 sh (unchged)
John Hussman 50,800 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Jerome Dodson 646,000 sh (unchged)
Tom Gayner Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 136,224 sh (-38.74%)
Joel Greenblatt 416,251 sh (-22.53%)
John Buckingham 68,001 sh (-2.13%)
Pioneer Investments 7,997,148 sh (-5.84%)
Eaton Vance Worldwide Health Sciences Fund 378,226 sh (-25.24%)
Jim Simons 2,752,400 sh (-45.31%)
» More
Q3 2018

GILD Guru Trades in Q3 2018

David Carlson 490,000 sh (+8.89%)
Charles Brandes 70,771 sh (+14.34%)
Diamond Hill Capital 1,753,565 sh (+7.44%)
Jim Simons 4,489,648 sh (+63.12%)
John Rogers 2,404,049 sh (+3.21%)
Stanley Druckenmiller 1,464,900 sh (+21.54%)
John Buckingham 69,146 sh (+1.68%)
Jeff Auxier 11,550 sh (+36.28%)
Dodge & Cox 16,450,181 sh (+1.17%)
Ken Fisher 559,555 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 378,226 sh (unchged)
Ronald Muhlenkamp 2,200 sh (unchged)
Murray Stahl 9,000 sh (unchged)
Steven Cohen 25,000 sh (unchged)
Jeremy Grantham Sold Out
Jerome Dodson 343,776 sh (-46.78%)
T Rowe Price Equity Income Fund 3,490,000 sh (-1.13%)
John Hussman 25,800 sh (-49.21%)
Mario Gabelli 14,880 sh (-0.67%)
Ronald Muhlenkamp 135,401 sh (-0.60%)
Ray Dalio 34,650 sh (-33.77%)
Pioneer Investments 6,544,475 sh (-18.16%)
Julian Robertson 34,460 sh (-10.52%)
NWQ Managers 707,557 sh (-1.89%)
Joel Greenblatt 360,239 sh (-13.46%)
Steven Cohen 1,247,282 sh (-60.66%)
Paul Tudor Jones 20,274 sh (-27.22%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OCSE:NOVO B, NAS:AMGN, NAS:CELG, ASX:CSL, NAS:BIIB, LSE:SHP, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:GILD.Austria, GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Italy, GILD.Mexico, GILD.Switzerland,
Headquarter Location:USA
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Guru Investment Theses on Gilead Sciences Inc

Jerome Dodson Comments on Gilead Sciences - Oct 31, 2018

Gilead Sciences (NASDAQ:GILD), the biotechnology firm that makes therapies for HIV and Hepatitis C (HCV), contributed 73 bps to the Fund’s return, as the stock climbed from $70.84 to $77.21 for a total return of 9.8%. Despite the announcement that CEO John Milligan will leave the company by year end, the stock was up, as Gilead reported strong demand for its HIV medicine and promising data from its clinical trials. After two years of revenue declines, investors were encouraged that sales might start moving higher again. Demand trends in the HIV market remained healthy and management reported a more stable and predictable HCV business, with pricing pressure and share losses moderating.

From Jerome Dodson (Trades, Portfolio)'s third-quarter 2018 Endeavor Fund shareholder letter.

Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead Sciences - Oct 25, 2017

Our best performer was Gilead Sciences (NASDAQ:GILD), the biotechnology firm that makes therapies for HIV and hepatitis C. Its stock jumped 14.5% from $70.78 to $81.02, contributing 70 basis points to the Fund’s return. In August, the company acquired Kite Pharma for $12 billion. Kite Pharma is a leader in cellular therapy, a game-changing new cancer treatment that harnesses the body’s own immune system to fight cancer. The acquisition establishes Gilead as a leader in a fast-growing field with huge opportunities.



From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Gilead - Jan 25, 2017

Our other laggard was Gilead (NASDAQ:GILD), a biotechnology firm that makes therapies for HIV and Hepatitis C. Gilead sliced 98 basis points off the Fund’s return, as its stock declined 29.2%, from $101.19 to $71.61. The stock dropped due to weakness in the Hepatitis C business, as pricing came under pressure due to increased competition, and the patient population fell because Gilead’s drugs cure patients of this damaging disease. The stock is on the bargain table, and the company has a strong balance sheet and a proven track record of innovation, so we increased our position throughout the year.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Will 2019 Be Gilead's Turnaround Year? With a new pipeline of drugs expected over the next two years, growth is coming back again
Barring some miracle new drug breakthrough announcement, Gilead (NASDAQ:GILD)'s 2018 has been one to forget. The drugmaker turned HIV into a manageable chronic ailment and is developing a cure for hepatitis C. In the annals of history, Gilead will be remembered by the future robot overlords as prolonging human life long enough to create the singularity. Read more...
Jerome Dodson Comments on Gilead Sciences Guru stock highlight
Gilead Sciences (NASDAQ:GILD), the biotechnology firm that makes therapies for HIV and Hepatitis C (HCV), contributed 73 bps to the Fund’s return, as the stock climbed from $70.84 to $77.21 for a total return of 9.8%. Despite the announcement that CEO John Milligan will leave the company by year end, the stock was up, as Gilead reported strong demand for its HIV medicine and promising data from its clinical trials. After two years of revenue declines, investors were encouraged that sales might start moving higher again. Demand trends in the HIV market remained healthy and management reported a more stable and predictable HCV business, with pricing pressure and share losses moderating. Read more...
Investor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brink's, Fortive, Asbury Automotive Group, and Helmerich & Payne — Discovering Underlying Factors of Influence
Risk-Reward With Gilead Sciences Even with a 3% dividend yield, the stock is too expensive
Gilead Sciences (NASDAQ:GILD) has been up and down a lot over the last five years. A big reason is the company's Hepatitis C drug, which had a blockbuster year in sales during 2015, only to suffer price pressure ever since. Now, that business segment is in full-blown decline with sales coming in at $1.0 billion during the company's second quarter of 2018, off from the $2.9 billion result just a year ago. Read more...
Revisiting Gilead Sciences Three percent yield, 11x forward earnings multiple, 2 big name gurus
Gilead Sciences (NASDAQ:GILD) has experienced significant declines in revenue and net income over the last few years; however, when judged over a five- and 10-year period, the company is rock solid. In fact, Steven Cohen (Trades, Portfolio)’s Point72 owns 3 million shares and Jim Simons (Trades, Portfolio)’ Renaissance Technologies has 5 million shares. Read more...
Antifragility, Path Dependency and Value Investing (Part 2) Path dependency is a very important concept
Path dependency is a very important concept. It’s something we constantly think about, and thus, we’ll take a small detour to explore it.
Read more...
Gilead Sciences to Release 4th-Quarter Earnings Analysts forecast a 38% decline in earnings
It is time for Gilead Sciences, Inc. (NASDAQ:GILD) to announce its earnings for the fourth quarter of fiscal 2017. Read more...

Ratios

vs
industry
vs
history
PE Ratio 55.87
GILD's PE Ratio is ranked lower than
69% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. GILD: 55.87 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.67  Med: 16.4 Max: 64.34
Current: 55.87
6.67
64.34
Forward PE Ratio 10.35
GILD's Forward PE Ratio is ranked higher than
86% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. GILD: 10.35 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 55.87
GILD's PE Ratio without NRI is ranked lower than
68% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. GILD: 55.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.67  Med: 16.4 Max: 64.34
Current: 55.87
6.67
64.34
Price-to-Owner-Earnings 12.38
GILD's Price-to-Owner-Earnings is ranked higher than
81% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. GILD: 12.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.52  Med: 13.09 Max: 54.5
Current: 12.38
5.52
54.5
PB Ratio 3.79
GILD's PB Ratio is ranked lower than
53% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GILD: 3.79 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 3.69  Med: 6.72 Max: 15.31
Current: 3.79
3.69
15.31
PS Ratio 3.95
GILD's PS Ratio is ranked higher than
73% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 3.95 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.95  Med: 5.1 Max: 12.5
Current: 3.95
2.95
12.5
Price-to-Free-Cash-Flow 11.14
GILD's Price-to-Free-Cash-Flow is ranked higher than
84% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. GILD: 11.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.45  Med: 12.01 Max: 48.02
Current: 11.14
5.45
48.02
Price-to-Operating-Cash-Flow 10.00
GILD's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. GILD: 10.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.24  Med: 11.56 Max: 45.09
Current: 10
5.24
45.09
EV-to-EBIT 8.82
GILD's EV-to-EBIT is ranked higher than
75% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. GILD: 8.82 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.3  Med: 9.9 Max: 32.5
Current: 8.82
5.3
32.5
EV-to-EBITDA 7.68
GILD's EV-to-EBITDA is ranked higher than
76% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. GILD: 7.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 9.3 Max: 30.2
Current: 7.68
5
30.2
EV-to-Revenue 3.97
GILD's EV-to-Revenue is ranked higher than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. GILD: 3.97 )
Ranked among companies with meaningful EV-to-Revenue only.
GILD' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.1  Med: 5.5 Max: 13.1
Current: 3.97
3.1
13.1
PEG Ratio 1.29
GILD's PEG Ratio is ranked higher than
70% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. GILD: 1.29 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.45 Max: 3.87
Current: 1.29
0.11
3.87
Shiller PE Ratio 13.82
GILD's Shiller PE Ratio is ranked higher than
87% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. GILD: 13.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.73  Med: 41.03 Max: 304.25
Current: 13.82
13.73
304.25
Current Ratio 3.45
GILD's Current Ratio is ranked lower than
64% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. GILD: 3.45 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 6.83 Max: 57.67
Current: 3.45
1.08
57.67
Quick Ratio 3.37
GILD's Quick Ratio is ranked lower than
61% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. GILD: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 6.29 Max: 57.67
Current: 3.37
0.82
57.67
Days Inventory 72.45
GILD's Days Inventory is ranked higher than
65% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. GILD: 72.45 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 72.45  Med: 219.93 Max: 247.35
Current: 72.45
72.45
247.35
Days Sales Outstanding 56.76
GILD's Days Sales Outstanding is ranked higher than
59% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. GILD: 56.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.84  Med: 68.99 Max: 84.93
Current: 56.76
53.84
84.93
Days Payable 46.64
GILD's Days Payable is ranked lower than
59% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. GILD: 46.64 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 46.64  Med: 158.55 Max: 207.21
Current: 46.64
46.64
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.34
GILD's Dividend Yield % is ranked higher than
90% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. GILD: 3.34 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.36  Med: 2.54 Max: 3.35
Current: 3.34
0.36
3.35
Dividend Payout Ratio 1.83
GILD's Dividend Payout Ratio is ranked lower than
92% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. GILD: 1.83 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.19 Max: 1.83
Current: 1.83
0.11
1.83
Forward Dividend Yield % 3.25
GILD's Forward Dividend Yield % is ranked higher than
90% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. GILD: 3.25 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.28
GILD's 5-Year Yield-on-Cost % is ranked higher than
74% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. GILD: 3.28 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36  Med: 2.54 Max: 3.35
Current: 3.28
0.36
3.35
3-Year Average Share Buyback Ratio 4.40
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. GILD: 4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.6  Med: -3.25 Max: 6.1
Current: 4.4
-25.6
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 35.66
GILD's Price-to-Tangible-Book is ranked lower than
99% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. GILD: 35.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 8.56 Max: 214.73
Current: 35.66
1.51
214.73
Price-to-Intrinsic-Value-Projected-FCF 0.46
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. GILD: 0.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.46  Med: 1.9 Max: 20.83
Current: 0.46
0.46
20.83
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.96
GILD's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
61% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GILD: 1.96 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
GILD' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.67  Med: 1.1 Max: 3.86
Current: 1.96
0.67
3.86
Price-to-Median-PS-Value 0.78
GILD's Price-to-Median-PS-Value is ranked higher than
61% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. GILD: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 2.25 Max: 45
Current: 0.78
0.61
45
Price-to-Peter-Lynch-Fair-Value 2.40
GILD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
53% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. GILD: 2.40 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 0.98 Max: 9.13
Current: 2.4
0.29
9.13
Price-to-Graham-Number 9.42
GILD's Price-to-Graham-Number is ranked lower than
96% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. GILD: 9.42 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 3.46 Max: 15.78
Current: 9.42
1.56
15.78
Earnings Yield (Greenblatt) % 11.35
GILD's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. GILD: 11.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 10.1 Max: 18.8
Current: 11.35
3.1
18.8
Forward Rate of Return (Yacktman) % 32.98
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. GILD: 32.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.9  Med: 24.7 Max: 33.3
Current: 32.98
13.9
33.3

More Statistics

Revenue (TTM) (Mil) $22,281.00
EPS (TTM) $ 1.20
Beta1.40
Volatility28.14%
52-Week Range $64.27 - 89.54
Shares Outstanding (Mil)1,293.62

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 21,686 22,179 23,321 24,988
EBIT (Mil $) 10,661 11,438 12,260
EBITDA (Mil $) 11,968 12,704 13,468
EPS ($) 5.50 6.10 7.07 9.61
EPS without NRI ($) 5.50 6.10 7.07 9.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
20.15%
Dividends per Share ($) 2.29 2.41 2.30

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}